-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
API refers to any substance or mixture of substances used in the manufacture of drugs, and when used in pharmaceuticals, it is used as an active ingredient of drugs.
In the process of pharmaceutical production, APIs are indispensable
.
According to the "Investment Environment and Investment Prospect Forecast Analysis Report of the API Industry for 2020-2024" released by the New Sijie Industry Research Center, in recent years, as the number of patented drugs expired, the number of generic drugs has increased.
It has also risen rapidly, and the API market is ushering in huge market opportunities, and the output of APIs will continue to grow
.
However, some analysts also pointed out that how to deal with the overcapacity of APIs in the future and how to remain invincible in the development of internationalization are important topics that China's API companies need to discuss
.
For the future development, it is very important for API companies to think carefully and plan ahead
.
Among them, an important step that companies need to do is to increase innovation and research and development efforts
.
The industry suggests that API companies should develop products with complex structures and high value-added sub-categories to obtain a certain technical threshold; process development should be upgraded with high performance, low pollution, and greenness, such as biotechnology and Enzymatic process; manufacturing methods are upgraded to intelligent manufacturing, such as continuous, automated, and modular
.
The author has learned that some companies are also actively innovating and upgrading
.
For example, Tianke (Jingzhou) Pharmaceutical Co.
, Ltd.
is a vivid case of Jingzhou Development Zone's practice of green development and high-quality development in the "reform to relocation"
.
In the same year, Tianjin Pharmaceutical Research Institute, a member of China Merchants Group, cooperated with Nengte Technology Co.
, Ltd.
to register and set up Tianke (Jingzhou) Pharmaceutical Co.
, Ltd.
, with an investment of 770 million yuan to build a green pharmaceutical industry base project covering an area of 230 acres
.
The two parties are committed to building a high-end API industrialization base that meets national GMP requirements and meets EU and US FDA standards, aiming to achieve green, intelligent, lean and globalized production of technical materials
.
It is reported that after the completion of the first phase of the project, it will have two intelligent and digital production workshops of 16,000 square meters and an environmental protection center of 5,000 square meters; after it is officially put into production, it can produce 8 to 12 varieties of products involving nervous system, hypertension, Diabetes, asthma, cardiovascular and cerebrovascular and other fields
.
Three to five years after the official production, the annual production capacity of green raw materials is expected to exceed 50 tons, with an output value of 1.
3 billion yuan
.
Innovation is the core competitiveness of enterprise development.
API companies take precautions and continue to increase innovation and research and development to achieve long-term development
.
However, in addition to the need to increase innovation, analysts also pointed out that API companies should continue to optimize the supply chain system, actively undertake pharmaceutical division of labor and collaboration, deeply embed in the global pharmaceutical industry chain, and establish long-term and strong partnerships with upstream and downstream companies.
.
For example, Guobang Pharmaceutical is from a strategic point of view and will continue to add advantageous varieties through horizontal replication of products; starting from APIs, through the vertical expansion of the industry chain, the overall competitive advantage will be enhanced; the development of innovative models that are compatible with the industry will be based on From standard innovation to combination innovation, and ultimately to achieve independent innovation
.
The raw material drug market has a broad prospect.
China has now become a large-scale raw material drug producer and exporter in the world, providing about 30% of the global raw material drug production capacity, and the export scale is close to about 20% of the global raw material drug market share
.
However, analysts pointed out that while China's API companies attach importance to the international market, they should also take into account the domestic market
.
Only when the raw material pharmaceutical companies make efforts in both foreign and domestic markets can they be better protected
.
For example, the relevant person in charge of Northeast Pharmaceutical said that the company will continue to adjust its sales model while actively expanding the international market, and deepen the domestic market
.
In July, sales of the company's preparation business, which accounts for a large proportion of the company's overall operations, increased by more than 20% year-on-year
.
In the process of pharmaceutical production, APIs are indispensable
.
According to the "Investment Environment and Investment Prospect Forecast Analysis Report of the API Industry for 2020-2024" released by the New Sijie Industry Research Center, in recent years, as the number of patented drugs expired, the number of generic drugs has increased.
It has also risen rapidly, and the API market is ushering in huge market opportunities, and the output of APIs will continue to grow
.
However, some analysts also pointed out that how to deal with the overcapacity of APIs in the future and how to remain invincible in the development of internationalization are important topics that China's API companies need to discuss
.
For the future development, it is very important for API companies to think carefully and plan ahead
.
Among them, an important step that companies need to do is to increase innovation and research and development efforts
.
The industry suggests that API companies should develop products with complex structures and high value-added sub-categories to obtain a certain technical threshold; process development should be upgraded with high performance, low pollution, and greenness, such as biotechnology and Enzymatic process; manufacturing methods are upgraded to intelligent manufacturing, such as continuous, automated, and modular
.
The author has learned that some companies are also actively innovating and upgrading
.
For example, Tianke (Jingzhou) Pharmaceutical Co.
, Ltd.
is a vivid case of Jingzhou Development Zone's practice of green development and high-quality development in the "reform to relocation"
.
In the same year, Tianjin Pharmaceutical Research Institute, a member of China Merchants Group, cooperated with Nengte Technology Co.
, Ltd.
to register and set up Tianke (Jingzhou) Pharmaceutical Co.
, Ltd.
, with an investment of 770 million yuan to build a green pharmaceutical industry base project covering an area of 230 acres
.
The two parties are committed to building a high-end API industrialization base that meets national GMP requirements and meets EU and US FDA standards, aiming to achieve green, intelligent, lean and globalized production of technical materials
.
It is reported that after the completion of the first phase of the project, it will have two intelligent and digital production workshops of 16,000 square meters and an environmental protection center of 5,000 square meters; after it is officially put into production, it can produce 8 to 12 varieties of products involving nervous system, hypertension, Diabetes, asthma, cardiovascular and cerebrovascular and other fields
.
Three to five years after the official production, the annual production capacity of green raw materials is expected to exceed 50 tons, with an output value of 1.
3 billion yuan
.
Innovation is the core competitiveness of enterprise development.
API companies take precautions and continue to increase innovation and research and development to achieve long-term development
.
However, in addition to the need to increase innovation, analysts also pointed out that API companies should continue to optimize the supply chain system, actively undertake pharmaceutical division of labor and collaboration, deeply embed in the global pharmaceutical industry chain, and establish long-term and strong partnerships with upstream and downstream companies.
.
For example, Guobang Pharmaceutical is from a strategic point of view and will continue to add advantageous varieties through horizontal replication of products; starting from APIs, through the vertical expansion of the industry chain, the overall competitive advantage will be enhanced; the development of innovative models that are compatible with the industry will be based on From standard innovation to combination innovation, and ultimately to achieve independent innovation
.
The raw material drug market has a broad prospect.
China has now become a large-scale raw material drug producer and exporter in the world, providing about 30% of the global raw material drug production capacity, and the export scale is close to about 20% of the global raw material drug market share
.
However, analysts pointed out that while China's API companies attach importance to the international market, they should also take into account the domestic market
.
Only when the raw material pharmaceutical companies make efforts in both foreign and domestic markets can they be better protected
.
For example, the relevant person in charge of Northeast Pharmaceutical said that the company will continue to adjust its sales model while actively expanding the international market, and deepen the domestic market
.
In July, sales of the company's preparation business, which accounts for a large proportion of the company's overall operations, increased by more than 20% year-on-year
.
